Belgium Diabetes Care Devices Investment Opportunities, Analysis and Forecasts to 2012

Product Code GMD07487
Publication Date November 2008
Publisher Global Markets Direct
Product Type Report
Pages 80
ISBN Number not applicable
Change currency
PDF £1,895.00 €2,282 $2,996 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

Belgium Diabetes Care Devices Investment Opportunities, Analysis and Forecasts to 2012

Belgium Diabetes Care Devices Investment Opportunities, Analysis and Forecasts to 2012

Summary

This report is an essential source for indepth information and data relating to the Belgium diabetes care devices market. It also offers detailed and comprehensive coverage of market revenue, volume, distribution and company share information; and latest news, financial deals and pipeline products information of each of the key subsegments of the diabetes care devices in Belgium

Scope

  • The report provides diabetes care devices information broken down into detailed categories and segments in Belgium.
  • Total revenues, products sold, end users, and average pricing.
  • Market shares of all the key competitors.
  • Key pipeline products that are set to shape the market, broken down by sector.
  • Information on the top medical equipment companies in the sector in the country covering business description, strategic analysis, and financial information.
  • Healthcare structure, regulatory environment, approval process, pricing trends and reimbursement.
  • Product and brand updates, strategy changes, R&D projects, corporate expansions and contractions and regulatory changes.
  • Key mergers and acquisitions, partnerships, private equity investments and IPOs.
  • Customer, hospitals and physicians data.

Reasons to buy

  • Gain a strong understanding of the diabetes care devices market in Belgium.
  • Evaluate and compare the attractiveness of the market in the country.
  • Identify growth segments and opportunities in each industry sector within the country.
  • Evaluate the pipeline of key products that will change the sector, and identify threats and opportunities before the products are launched in the country.
  • Analyze the competitiveness of the market in the country and identify hotspots.
  • Develop strategies based on the latest product, brand, expansion and research and development news in the country.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the market in the country.
  • Identify and analyze the strengths and weaknesses of the industry incumbents in the country.

Contents

  • 1 Table of Contents
  • 1.1 List of Tables
  • 1.2 List of Figures
  • 2 Introduction
    • 2.1 What Is This Report About?
  • 3 Definitions of the Markets Covered in the Report
    • 3.1 Diabetes Care Devices
    • 3.2 Glucose Monitoring
      • 3.2.1 Blood Glucose Meter
      • 3.2.2 Blood Glucose Strips
    • 3.3 Insulin Delivery
      • 3.3.1 Insulin Pen
      • 3.3.2 Insulin Pump
      • 3.3.3 Insulin Syringes
  • 4 Healthcare Sector Review
    • 4.1 Healthcare Expenditure
    • 4.2 Healthcare Infrastructure
      • 4.2.1 Healthcare Personnel Data
      • 4.2.2 Healthcare Facilities Data
    • 4.3 Healthcare Policy
  • 5 Regulation System
    • 5.1 Medical Equipment Approval Process
      • 5.1.1 Classification
      • 5.1.2 Conformity Assessment Process
    • 5.2 Notification Fee
  • 6 Pricing and Reimbursement
    • 6.1 Reimbursement Policies
  • 7 Distribution Structure
  • 8 Diabetes Care Devices In Belgium
    • 8.1 Diabetes Care Devices Cross Country Comparison (20002012)
    • 8.2 Diabetes Care Devices, Belgium, Overall Revenues ($ mn), 20002012
    • 8.3 Diabetes Care Devices, Belgium, Category Volume (Units), 20002012
    • 8.4 Diabetes Care Devices, Belgium Company share (20062007)
  • 9 Glucose Monitoring In Belgium
    • 9.1 Glucose Monitoring Overall Revenue (20002012)
    • 9.2 Glucose Monitoring Overall Volume (20002012)
    • 9.3 Glucose Monitoring Average Price (20002012)
    • 9.4 Glucose Monitoring Distribution Share (20062007)
    • 9.5 Glucose Monitoring, Belgium, Company Share (20062007)
  • 10 Insulin Delivery In Belgium
    • 10.1 Insulin Delivery Overall Revenue (20002012)
    • 10.2 Insulin Delivery Overall Volume (20002012)
    • 10.3 Insulin Delivery Average Price (20002012)
    • 10.4 Insulin Delivery Distribution Share (20062007)
    • 10.5 Insulin Delivery, Belgium, Company Share (20062007)
  • 11 F. HoffmannLa Roche Ltd. Company Profile
    • 11.1 Company Overview
    • 11.2 Value Chain Analysis
      • 11.2.1 Manufacturing
      • 11.2.2 Product Development
      • 11.2.3 Sales and Marketing
  • 12 Novo Nordisk A/S Company Profile
    • 12.1 Company Overview
      • 12.1.1 Novo Nordisk A/S Pipeline Products by Equipment Type
      • 12.1.2 Novo Nordisk A/S Pipeline Products by Development Stage
      • 12.1.3 Novo Nordisk A/S Pipeline Products by Therapy Area
      • 12.1.4 Novo Nordisk A/S Pipeline Products by Clinical Trials
  • 13 LifeScan, Inc. Company Profile
    • 13.1 Company Overview
      • 13.1.1 LifeScan, Inc. Pipeline Products by Equipment Type
      • 13.1.2 LifeScan, Inc. Pipeline Products by Development Stage
      • 13.1.3 LifeScan, Inc. Pipeline Products by Therapy Area
      • 13.1.4 LifeScan, Inc. Pipeline Products by Clinical Trials
      • 13.1.5 LifeScan, Inc. Pipeline Products by News Summary
  • 14 Abbott Laboratories Company Profile
    • 14.1 Company Overview
    • 14.2 Value Chain Analysis
      • 14.2.1 Manufacturing
      • 14.2.2 Product Development
      • 14.2.3 Sales and Marketing
      • 14.2.4 Abbott Laboratories Pipeline Products by Equipment Type
      • 14.2.5 Abbott Laboratories Pipeline Products by Development Stage
      • 14.2.6 Abbott Laboratories Pipeline Products by Therapy Area
      • 14.2.7 Abbott Laboratories Pipeline Products by Clinical Trials
      • 14.2.8 Abbott Laboratories Pipeline Products by News Summary
  • 15 Bayer HealthCare AG Company Profile
    • 15.1 Company Overview
    • 15.2 Value Chain Analysis
      • 15.2.1 Manufacturing
      • 15.2.2 Product Development
      • 15.2.3 Sales and Marketing
    • 15.3 Bayer HealthCare AG Pipeline Products
      • 15.3.1 Bayer HealthCare AG Pipeline Products by Equipment Type
      • 15.3.2 Bayer HealthCare AG Pipeline Products by Development Stage
      • 15.3.3 Bayer HealthCare AG Pipeline Products by Therapy Area
      • 15.3.4 Bayer HealthCare AG Pipeline Products by News Summary
  • 16 Eli Lilly and Company Company Profile
    • 16.1 Company Overview
    • 16.2 Value Chain Analysis
      • 16.2.1 Manufacturing
      • 16.2.2 Product Development
      • 16.2.3 Sales and Marketing
      • 16.2.4 Eli Lilly and Company Pipeline Products by Equipment Type
      • 16.2.5 Eli Lilly and Company Pipeline Products by Development Stage
      • 16.2.6 Eli Lilly and Company Pipeline Products by Therapy Area
    • 17.1 Global Markets Direct Research Methodology
    • 17.2 Coverage
    • 17.3 Secondary Research
    • 17.4 Primary Research
    • 17.5 Models
    • 17.6 Forecasts
    • 17.7 Expert Panels
    • 17.8 Currency Conversion
    • 17.9 Contact Us
    • 17.10 Disclaimer
  • 1.1 List of Tables
    • Table 1: Hospitals and Hospital Beds in Belgium, 2005
    • Table 2: Number of Doctors by Specialty in Belgium, 20032007
    • Table 3: Number of Hospital Wards by Specialty in Belgium, 20032007
    • Table 4: Medical Equipment Notification Fee in Belgium, 2007
    • Table 5: Diabetes Care Devices Cross Country Comparison (20002012)
    • Table 6: Diabetes Care Devices, Belgium, Overall Revenues ($ mn), 20002012
    • Table 7: Diabetes Care Devices, Belgium, Portfolio Analysis, 20002012
    • Table 8: Diabetes Care Devices, Belgium, Overall Revenues ($ mn), Historic, 20002007
    • Table 9: Diabetes Care Devices, Belgium, Overall Revenues ($ mn), Forecast, 20072012
    • Table 10: Diabetes Care Devices, Belgium, Category Volume (Units), 20002012
    • Table 11: Diabetes Care Devices, Belgium, Category Volume (Units), Historic, 20002007
    • Table 12: Diabetes Care Devices, Belgium, Category Volume (Units), Forecast, 20072012
    • Table 13: Diabetes Care Devices, Belgium Company share by Revenue ($ mn), 20062007
    • Table 14: Glucose Monitoring, Belgium, Revenue ($ mn) by Segment, Historic, 20002007
    • Table 15: Glucose Monitoring, Belgium, Revenue ($ mn) by Segment, Forecast, 20072012
    • Table 16: Glucose Monitoring, Belgium, Overall Volume (Units), Historic, 20002007
    • Table 17: Glucose Monitoring, Belgium, Overall Volume (Units), Forecast, 20072012
    • Table 18: Glucose Monitoring, Belgium, Average Price ($), Historic, 20002007
    • Table 19: Glucose Monitoring, Belgium, Average Price ($), Forecast, 20072012
    • Table 20: Glucose Monitoring, Belgium, Distribution Share by Revenue ($mn), 20062007
    • Table 21: Glucose Monitoring, Belgium, Company Share by Revenue ($ mn), 20062007
    • Table 22: Insulin Delivery, Belgium, Revenue ($ mn) by Segment, Historic, 20002007
    • Table 23: Insulin Delivery, Belgium, Revenue ($ mn) by Segment, Forecast, 20072012
    • Table 24: Insulin Delivery, Belgium, Overall Volume (Units), Historic, 20002007
    • Table 25: Insulin Delivery, Belgium, Overall Volume (Units), Forecast, 20072012
    • Table 26: Insulin Delivery, Belgium, Average Price ($), Historic, 20002007
    • Table 27: Insulin Delivery, Belgium, Average Price ($), Forecast, 20072012
    • Table 28: Insulin Delivery, Belgium, Distribution Share by Revenue ($mn), 20062007
    • Table 29: Insulin Delivery, Belgium, Company Share by Revenue ($ mn), 20062007
    • Table 30: Novo Nordisk A/S Pipeline Products by Equipment Type
    • Table 31: Novo Nordisk A/S Pipeline Products By Development Stage
    • Table 32: Novo Nordisk A/S Pipeline Products By Therapy Area
    • Table 33: Novo Nordisk A/S Pipeline Products By Clinical Trials
    • Table 34: LifeScan, Inc. Pipeline Products by Equipment Type
    • Table 35: LifeScan, Inc. Pipeline Products by Development Stage
    • Table 36: LifeScan, Inc. Pipeline Products By Therapy Area
    • Table 37: LifeScan, Inc. Pipeline Products By Clinical Trials
    • Table 38: LifeScan, Inc. Pipeline Products By News Summaries
    • Table 39: Abbott Laboratories Pipeline Products by Equipment Type
    • Table 40: Abbott Laboratories Pipeline Products By Development Stage
    • Table 41: Abbott Laboratories Pipeline Products By Therapy Area
    • Table 42: Abbott Laboratories Pipeline Products By Clinical Trials
    • Table 43: Abbott Laboratories Pipeline Products By News Summaries
    • Table 44: Bayer HealthCare AG Pipeline Products by Equipment Type
    • Table 45: Bayer HealthCare AG Pipeline Products By Development Stage
    • Table 46: Bayer HealthCare AG Pipeline Products By Therapy Area
    • Table 47: Bayer HealthCare AG Pipeline Products By News Summaries
    • Table 48: Eli Lilly and Company Pipeline Products by Equipment Type
    • Table 49: Eli Lilly and Company Pipeline Products by Development Stage
    • Table 50: Eli Lilly and Company Pipeline Products By Therapy Area
    • Table 51: Currency Conversion from USD to Local Currency at 2007 Constant Rate
  • 1.2 List of Figures
    • Figure 1: Total Healthcare Expenditure in Belgium, 2000 2006
    • Figure 2: Structure of Healthcare System in Belgium, 2007
    • Figure 3: Flowchart for Classification of Noninvasive Devices in Belgium, 2007
    • Figure 4: Flowchart for Classification of Invasive Devices in Belgium, 2007
    • Figure 5: Flowchart for Classification of Invasive Devices in Belgium, 2007
    • Figure 6: Flowchart for Classification of Invasive Devices in Belgium, 2007
    • Figure 7: Flowchart for Classification of Invasive Devices in Belgium, 2007
    • Figure 8: Flowchart for Classification of Active Devices in Belgium, 2007
    • Figure 9: Flowchart for Classification of Active Devices in Belgium, 2007
    • Figure 10: Flowchart for Classification of Devices except Noninvasive, Invasive and Active Devices in Belgium, 2007
    • Figure 11: Conformity Assessment of ClassI Medical Devices in Belgium, 2007
    • Figure 12: Conformity Assessment of ClassIIa Medical Devices in Belgium, 2007
    • Figure 13: Conformity Assessment of ClassIIb Medical Devices in Belgium, 2007
    • Figure 14: Conformity Assessment of ClassIII Medical Devices in Belgium, 2007
    • Figure 15: Diabetes Care Devices Cross Country Comparison (20002012)
    • Figure 16: Diabetes Care Devices, Belgium, Overall Revenues ($ mn), 20002012
    • Figure 17: Diabetes Care Devices, Belgium, Portfolio Analysis, 20002012
    • Figure 18: Diabetes Care Devices, Belgium, Overall Revenues ($ mn), Historic, 20002007
    • Figure 19: Diabetes Care Devices, Belgium, Overall Revenues ($ mn), Forecast, 20072012
    • Figure 20: Diabetes Care Devices, Belgium, Category Volume (Units), 20002012
    • Figure 21: Diabetes Care Devices, Belgium, Category Volume (Units), Historic, 20002007
    • Figure 22: Diabetes Care Devices, Belgium, Category Volume (Units), Forecast, 20072012
    • Figure 23: Diabetes Care Devices, Belgium Company share (%), 2007
    • Figure 24: Glucose Monitoring, Belgium, Revenue ($ mn) by Segment, Historic, 20002007
    • Figure 25: Glucose Monitoring, Belgium, Revenue ($ mn) by Segment, Forecast, 20072012
    • Figure 26: Glucose Monitoring, Belgium, Overall Volume (Units), Historic, 20002007
    • Figure 27: Glucose Monitoring, Belgium, Overall Volume (Units), Forecast, 20072012
    • Figure 28: Glucose Monitoring, Belgium, Company Share (%), 2007
    • Figure 29: Insulin Delivery, Belgium, Revenue ($ mn) by Segment, Historic, 20002007
    • Figure 30: Insulin Delivery, Belgium, Revenue ($ mn) by Segment, Forecast, 20072012
    • Figure 31: Insulin Delivery, Belgium, Company Share (%), 2007
    • Figure 32: F. HoffmannLa Roche Ltd Value Chain Analysis
    • Figure 33: Abbott Laboratories Value Chain Analysis
    • Figure 34: Bayer HealthCare AG Value Chain Analysis
    • Figure 35: Eli Lilly and Company Value Chain Analysis
    • Figure 36: Global Markets Direct Methodology